Co-morbidities: The heart of the matter

Chair

Stefan Esser

Clinic of Dermatology, Department of Venereology, University Hospital Essen

Speakers

Stefan Esser

Clinic of Dermatology, Department of Venereology, University Hospital Essen

Introduction

Olof Elvstam

Lund University

Detailed modelling of viremia exposure does not independently predict cardiovascular disease in people with HIV

Jienchi Dorward

University of Oxford

Risk of major cardiovascular events with dolutegravir versus efavirenz-based antiretroviral therapy: retrospective cohort analyses using routine, de-identified data from South Africa

Matthew Romo

U.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Research

Dolutegravir-containing antiretroviral therapy and incident hypertension: findings from a prospective cohort in Kenya, Nigeria, Tanzania, and Uganda

Shalom Kawonga Dunga

Elizabeth Glaser Pediatric Aids Foundation

Integrating non-communicable disease screening and treatment in antiretroviral clinics: insights from Malawi

Carl J. Fichtenbaum

University of Cincinnati

Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial

Stefan Esser

Clinic of Dermatology, Department of Venereology, University Hospital Essen

Olof Elvstam

Lund University

Jienchi Dorward

University of Oxford

Matthew Romo

U.S. Military HIV Research Program, CIDR, Walter Reed Army Institute of Research

Shalom Kawonga Dunga

Elizabeth Glaser Pediatric Aids Foundation

Carl J. Fichtenbaum

University of Cincinnati

Q&A and conclusion